A novel small molecular weight compound with a carbazole structure that demonstrates potent human immunodeficiency virus type-1 integrase inhibitory activity

Antiviral Chemistry and Chemotherapy

Volumn 16, Issue 6, 2005, Pages 363-373

  Yan, Hua ^a   Mizutani, Tomoko Chiba ^a   Nomura, Nobuhiko ^b   Takakura, Tadakazu ^b   Kitamura, Yoshihiro ^c   Miura, Hideka ^a   Nishizawa, Masako ^a   Tatsumi, Masashi ^a   Yamamoto, Naoki ^a   Sugiura, Wataru ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b TOYAMA CHEMICAL CO LTD   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

Antiretroviral drug; Carbazole; HIV 1; Integrase inhibitor

Indexed keywords

CARBAZOLE DERIVATIVE; ETHIDIUM BROMIDE; INTEGRASE; INTERCALATING AGENT;

ARTICLE; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; DRUG ACTIVITY; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; EVALUATION; HELA CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; IN VITRO STUDY; INHIBITION KINETICS; MOLECULAR WEIGHT; PRIORITY JOURNAL; STRUCTURE ANALYSIS; VIRUS INHIBITION; VIRUS REPLICATION;

EID: 28544442291     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632020501600603     Document Type: Article

References (39)

1. Balzarini J (2004) Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1. Current Topics in Medicinal Chemistry 4:921-944.
2. Burke CJ, Sanyal G, Bruner MW, Ryan JA, LaFemina RL, Robbins HL, Zeft AS, Middaugh CR & Cordingley MG (1992) Structural implications of spectroscopic characterization of a putative zinc finger peptide from HIV-1 integrase. The Journal of Biological Chemistry 267:9639-9644.
3. Cain BF, Baguley BC & Denny WA (1978) Potential antitumor agent. 28. deoxyribonucleic acid polyintercalating agents. Journal of Medicinal Chemistry 21:658-668.
4. Carrasco C, Vezin H, Wilson WD, Ren J, Chaires JB & Bailly C (2001) DNA binding properties of the indolocarbazole antitumor drug NB-506. Anticancer Drug Design 16:99-107.
5. Chun TW, Finzi D, Margolick J, Chadwick K, Schwartz D & Siliciano RF (1995) In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nature Medicine 1:1284-1290.
6. Craigie R, Hickman AB & Engelman A (1995) Integrase. in HIV: A Practical Approach - Volume 2: Biochemistry, Molecular Biology, and Drug Discovery; pp. 53-71. Edited by J Karn. New York: Oxford University Press.
7. Dayam R & Neamati N (2003) Small-molecule HIV-1 integrase inhibitors: the 2001-2002 update. Current Pharmacology Design 9:1789-1802.
8. De Clercq E (1992) HIV inhibitors targeted at the reverse transcriptase. AIDS Research and Human Retroviruses 8:119-134.
9. Dziegielewski J, Slusarski B, Konitz A, Skladanowski A & Konopa J (2002) Intercalation of imidazoacridinones to DNA and its relevance to cytotoxic and antitumor activity. Biochemical Pharmacology 63:1653-1662.
10. Engelman A & Craigie R (1992) Identification of conserved amino acid residues critical for human immunodeficiency virus type 1 integrase function in vitro. Journal of Virology 66:6361-6369.
11. Engelman A, Englund G, Orenstein JM, Martin MA & Craigie R (1995) Multiple effects of mutations in human immunodeficiency virus type 1 integrase on viral replication. Journal of Virology 69:2729-2736.
12. Engelman A, Hickman AB & Craigie R (1994) The core and carboxyl-terminal domains of the integrase protein of human immunodeficiency virus type 1 each contribute to nonspecific DNA binding. Journal of Virology 68:5911-5917.
13. Facompre M, Carrasco C, Colson P, Houssier C, Chisholm JD, Van Vranken DL & Bailly C (2002) DNA binding and topoisomerase I poisoning activities of novel disaccharide indolocarbazoles. Molecular Pharmacology 62:1215-1227.
14. Fukui K & Tanaka K (1996) The acridine ring selectively intercalated into a DNA helix at various types of abasic sites: double strand formation and photophysical properties. Nucleic Acids Research 24:3962-3967.
15. Furusaki A, Hashiba N, Matsumoto T, Hirano A, Iwai Y & Omura S (1978) X-ray crystal structure of staurosporine: a new alkaloid from a Streptomyces strains. Journal of the Chemical Society. Chemical Communications 800-801.
16. Furusaki A, Hashiba N, Matsumoto T, Hirano A, Iwai Y & Omura S (1982) The crystal and molecular structure of staurosporine, a new alkaloid from a Streptomyces strains. Bulletin of the Chemical Society of Japan 55:3681-3685.
17. Goldgur Y, Craigie R, Cohen GH, Fujiwara T, Yoshinaga T, Fujishita T, Sugimoto H, Endo T, Murai H & Davies DR (1999) Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design. Proceedings of the National Academy of Sciences, USA 96:13040-13043.
18. Grobler JA, Stillmock K, Hu B, Witmer M, Felock P, Espeseth AS, Wolfe A, Egbertson M, Bourgeois M, Melamed J, Wai JS, Young S, Vacca J & Hazuda DJ (2002) Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes. Proceedings of the National Academy of Sciences USA 99:6661-6666.
19. Hazuda DJ, Anthony NJ, Gomez RP, Jolly SM, Wai JS, Zhuang L, Fisher TE, Embrey M, Guare JP, Jr., Egbertson MS, Vacca JP, Huff JR, Felock PJ, Witmer MV, Stillmock KA, Danovich R, Grobler J, Miller MD, Espeseth AS, Jin L, Chen IW, Lin JH, Kassahun K, Ellis JD, Wong BK, Xu W, Pearson PG, Schleif WA, Cortese R, Emini E, Summa V, Holloway MK & Young SD (2004) A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. Proceedings of the National Academy of Sciences USA 101:11233-11238.
20. Hazuda DJ, Felock P, Witmer M, Wolfe A, Stillmock K, Grobler JA, Espeseth A, Gabryelski L, Schleif W, Blau C & Miller MD (2000) Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 287:646-650.
21. Imamichi T (2004) Action of anti-HIV drugs and resistance: reverse transcriptase inhibitors and protease inhibitors. Current Pharmaceutical Design 10:4039-4053.
22. Johnson AA, Marchand C & Pommier Y (2004) HIV-1 integrase inhibitors: a decade of research and two drugs in clinical trial. Current Topics in Medicinal Chemistry 4:1059-1077.
23. Khan E, Mack JP, Katz RA, Kulkosky J & Skalka AM (1991) Retroviral integrase domains: DNA binding and the recognition of LTR sequences. Nucleic Acids Research 19:851-860.
24. Kohl NE, Emini EA, Schleif WA, Davis LJ, Heimbach JC, Dixon RA, Scolnick EM & Sigal IS (1988) Active human immunodeficiency virus protease is required for viral infectivity. Proceedings of National Academy of Sciences USA 85:4686-4690.
25. LaFemina RL, Schneider CL, Robbins HL, Callahan PL, LeGrow K, Roth E, Schleif WA & Emini EA (1992) Requirement of active human immunodeficiency virus type 1 integrase enzyme for productive infection of human T-lymphoid cells. Journal of Virology 66:7414-7419.
26. Long BH, Rose WC, Vyas DM, Matson JA & Forenza S (2002) Discovery of antitumor indolocarbazoles: rebeccamycin, NSC 655649, and fluoroindolocarbazoles. Current Medicinal Chemistry. Anti-Cancer Agents 2:255-266.
27. Marotto A, Kim YS, Schulze E & Pindur U (2002) New indolocarbazoles as antitumour active compounds: evaluation of the target by experimental and theoretical studies. Pharmazie 57:194-197.
28. Oka S, Kodama M, Takeda H, Tomizuka N & Suzuki H (1986) Staurosporine, a potent platelet aggregation inhibitor form a Streptomyces species. Agricultural and Biological Chemistry 50:2723-2727.
29. Omura S, Iwai Y, Hirano A, Nakagawa A, Awaya J, Tsuchya H, Takahashi Y & Masuma R (1977) A new alkaloid AM-2282 of Streptomyces origin. Taxonomy, fermentation, isolation and preliminary characterization. The Journal of Antibiotics (Tokyo) 30:275-282.
30. Pluymers W, Pais G, Van Maele B, Pannecouque C, Fikkert V, Burke TR, Jr., De Clercq E, Witvrouw M, Neamati N & Debyser Z (2002) Inhibition of human immunodeficiency virus type 1 integration by diketo derivatives. Antimicrobial Agents and Chemotherapy 46:3292-3297.
31. Pommier Y, Marchand C & Neamati N (2000) Retroviral integrase inhibitors year 2000: update and perspectives. Antiviral Research 47:139-148.
32. Ross WE, Glaubiger D & Kohn KW (1979) Qualitative and quantitative aspects of intercalator-induced DNA strand breaks. Biochimica et Biophyssica Acta 562:41-50.
33. Ruscetti FW (1985) Immunopathology associated with human lymphotropic retroviruses. Survey and Synthesis of Pathology Research 4:216-226.
34. Schauer M & Billich A (1992) The N-terminal region of HIV-1 integrase is required for integration activity, but not for DNA-binding. Biochemical and Biophysical Research Communications 185:874-880.
35. Sunthitikawinsakul A, Kongkathip N, Kongkathip B, Phonnakhu S, Daly JW, Spande TF, Nimit Y & Rochanaruangrai S (2003) Coumarins and carbazoles from Clausena excavata exhibited antimycobacterial and antifungal activities. Planta Medica 69:155-157.
36. ++ dependent protein kinase. Biochemical and Biophysical Research Communications 135:397-402.
37. Tronchet JM & Seman M (2003) Non-nucleoside inhibitors of HIV-1 reverse transcriptase: from the biology of reverse transcription to molecular design. Current Topics in Medicinal Chemistry 3:1496-1511.
38. Wilson WD & Jones RL (1982) Interaction of actinomycin D, ethidium, quinacrine, daunorubicin, and tetralysine with DNA: 31P NMR chemical shift and relaxation investigation. Nucleic Acids Research 10:1399-1410.
39. Woerner AM & Marcus-Sekura CJ (1993) Characterization of a DNA binding domain in the C-terminus of HIV-1 integrase by deletion mutagenesis. Nucleic Acids Research 21:3507-3511.